Iovance Biotherapeutics analyst commentary at B. RileyFBR Iovance lifileucel data support melanoma optimism, says B. Riley FBR. B. Riley FBR analyst Madhu Kumar reiterates a Buy rating on Iovance Biotherapeutics with a $24 price target after the company presented Phase II lifileucel melanoma data this weekend. The analyst views the 30% confirmed overall response rate and early duration of response as "impressive" for the highly refractory post-PD-1 patients studied. The analyst says these results validate his optimism for the potentially registrational cohort 4 of lifileucel in melanoma, guided to start in early 2019.Read more at: https://thefly.com/landingPage...(Source theFly) * This stock has been on our trading list for a while now. Will continue to look for trades in this name. *** About the only Biotech stock up today ** $IOVA, Iovance Biotherapeutics, Inc. / H1 Disclosure: I may trade in the ticker symbols mentioned, both long or short. My articles represent my personal opinion and analysis and should not be taken as investment advice. Readers should do their own research before making decisions to buy or sell securities. Trading and investing include risks, including loss of principal. If you liked this article, please click the LIKE (thumbs up) button. Feel free to leave any comments, question, or opinions. Follow us and check back occasionally for additional articles or posts.